nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "ADHD"

 

FDA Approves New Treatment For ADHD In Pediatric Patients
April 2, 2021   

A U.S. Food and Drug Administration approves viloxazine extended-release capsules for the treatment of attention-deficit hyperactivity disorder in pediatric patients 6 to 17 years of age...
 Continue reading
FDA Approves New Once-Daily Treatment for ADHD
March 17, 2021   

The US Food and Drug Administration has approved a new, once-daily oral stimulant medication for treatment of attention deficit hyperactivity disorder (ADHD) in people aged 6 years and older. The new drug consists of a novel prodrug co-formulated with...
 Continue reading
Youth With ADHD May Have Increased Risk for Psychotic Disorders
March 8, 2021   

In a recent meta-analysis of 12 studies and 1.85 million participants, an increased risk of psychotic disorder was associated with a diagnosis of attention deficit hyperactivity disorder during childhood compared to participants without attention deficit hyperactivity disorder during childhood....
 Continue reading
Children With Congenital Heart Disease at Elevated Risk of Depression, Anxiety, ADHD
January 26, 2021   

A recent comparative cross-sectional study was conducted to examine the risk of mental health disorders (e.g. depression, anxiety, and attention deficit/hyperactivity disorder) in youth with congenital heart disease (CHD). Data was collected from...
 Continue reading (Members only)
Prevalence and Risk Factors Associated With Attention-Deficit/Hyperactivity Disorder Among US Black Individuals
September 24, 2020   

The worldwide prevalence of attention deficit/hyperactivity disorder (ADHD) is estimated to be 5.6%-7.2%. Prevalence rates of ADHD among Black individuals are reported to be lower than the rates of the general population. However, there is a paucity of primary studies with appropriate methodological design...
 Continue reading (Members only)
NEI Virtual Poster Library is Live!
July 13, 2020   

NEI has launched a Virtual Poster Library to fulfill the needs of poster presenters who had hoped to share their research and findings at medical conferences that have been cancelled due to the COVID-19 pandemic....
 Continue reading
FDA Permits Marketing of First Game-Based Digital Therapeutic to Improve Attention Function in Children with ADHD
June 29, 2020   

The US Food and Drug Administration has recently approved use of a game-based digital device for the treatment of ADHD in youths aged 8-12 years...
 Continue reading
Positive Results for Brainsway’s Feasability Study of Deep Transcranial Magnetic Stimulation in the Treatment of Adults with ADHD
March 10, 2020   

The results from their randomized controlled double-blind clinical trial assessing the efficacy and safety of the company’s proprietary H6-coil deep transcranial magnetic stimulation (dTMS) System for the treatment of adults with attention deficit hyperactivity disorder (ADHD)...
 Continue reading
Acetaminophen and the Risk of Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder in Childhood
February 21, 2020   

Studies have shown an association between self-reported maternal acetaminophen use during pregnancy and risk of attention-deficit/hyperactivity disorder and autism spectrum disorder in offspring; however...
 Continue reading
FDA Allows Marketing of First Device to Treat ADHD
April 26, 2019   

The US Food and Drug Administration (FDA) recently permitted marketing for the first medical device to treat attention deficit hyperactivity disorder (ADHD). The device, called the Monarch external Trigeminal Nerve Stimulation System (eTNS) is indicated by...
 Continue reading
1234
Top of Page